The Frost & Sullivan organised the third Global Partnership Summit on 'the Opportunities in Lifescience Molecules' at The Leela, Goa from May 21-23, 2007, in which the growth drivers and the strategies for catalysing sustainable growth and leadership in the pharmaceutical industry were discussed.
Started as a summit focusing on management and strategic issues related to pharmaceutical industry in the year 2005, the Global Partnership Summit- 2007 received tremendous response from the industry and surpassed all expectations in terms of size and the number of participants.
This year, the summit focused on addressing strategic issues on CRAMS in discovery and bio-specialties, business models for sustaining long-term partnerships beyond the initial short term relationships, strategies in deal making from discovery to manufacturing, process innovation, and others. The summit provided a tremendous opportunity for knowledge exchange through interactive case study analyses, workshops and panel discussions.
Both as a knowledge sharing platform and a high profile networking summit, this event offered key insights into the focus and direction of the industry and emerging opportunities. Panel discussions, growth workshops, case study analyses, etc. on areas such as strategy and deal making, opportunities for partnerships in discovery, process innovation, outsourcing, M&A, CRAMS in biologicals, PE investments in lifesciences, etc. were the major highlights. The event also served as a platform to focus upon strategic alliances, licensing or partnership opportunities.
With participation from both domestic and international companies like Ranbaxy, Cadila, Malladi Drugs, Wockhardt, Nicholas Piramal, Eli Lilly, Wyeth, sanofi aventis, Perkin Elmer, Boehringer Ingelheim, and many others, the summit was the ideal platform to interact with key executives of the top pharma and biotech companies. It also helped to gain a deeper insight into the opportunities and emerging areas that these key decision makers and the industry would consider over the coming years.